Amneal Pharmaceuticals (AMRX) Tops Q4 EPS by 3c ; Offers Guidance

Amneal Pharmaceuticals (NASDAQ: AMRX) reported Q4 EPS of $0.21, $0.03 better than the analyst estimate of $0.18. Revenue for the quarter came in at $814.32 million versus the consensus estimate of $806.02 million.

GUIDANCE:

Amneal Pharmaceuticals sees FY2026 EPS of $0.93-$1.03, versus the consensus of $0.94. Amneal Pharmaceuticals sees FY2026 revenue of $3.05-3.15 billion, versus the consensus of $3.21 billion.

For earnings history and earnings-related data on Amneal Pharmaceuticals (AMRX) click here.

You May Also Be Interested In

• FedEx falls 4% as FY2027 profit forecast misses expectations despite Q4 beat
• IBM extends two credit agreements totaling $10 billion by one year
• Glacier Bancorp (GBCI) Declares $0.33 Quarterly Dividend; 2.7% Yield